Sequential chemotherapy and icotinib as first-line treatment for advanced epidermal growth factor receptor-mutated non-small cell lung cancer

Table 1 Patient characteristics

	Icotinib	Chemotherapy + icotinib	Chemotherapy + icotinib, n = 34
			2DP	2PP	4DP	4PP
	n = 22	n = 34	n = 11	n = 10	n = 4	n = 9
Age (yr)	57.0 ± 7.4	52.7 ± 11.05	52.9 ± 11.5	49.8 ± 9.2	49.8 ± 13.7	57.1 ± 11.7
Sex
Male	11 (50.0)	9 (26.5)	2 (18.2)	2 (20.0)	2 (50.0)	3 (33.3)
Female	11 (50.0)	25 (73.5)	9 (81.8)	8 (80.0)	2 (50.0)	6 (66.7)
Stage
IIIB	0	1 (2.9)	0	0	0	1 (11.1)
IV	22 (100.0)	33 (97.1)	11 (100.0)	10 (100.0)	4 (100.0)	8 (88.9)
EGFR mutation
19 Del	12 (54.5)	19 (55.9)	5 (45.5)	5 (50.0)	4 (100.0)	5 (55.6)
21 L858R	7 (31.8)	14 (41.2)	5 (45.5)	5 (50.0)	0	4 (44.4)
Other	3 (13.6)	1 (2.9)	1 (9.1)	0	0	0
Smoking
Yes	6 (27.3)	4 (11.8)	1 (9.1)	1 (10.0)	1 (25.0)	1 (11.1)
No	15 (68.2)	30 (88.2)	10 (90.9)	9 (90.0)	3 (75.0)	8 (88.9)
Quit smoking	1 (4.5)	0	0	0	0	0
ECOG PS
0	5 (22.7)	6 (17.6)	1 (9.1)	2 (20.0)	0	3 (33.3)
1	13 (59.1)	25 (73.5)	7 (63.6)	8 (80.0)	4 (100.0)	6 (66.7)
2	2 (9.1)	0	0	0	0	0
Other	2 (9.1)	3 (8.8)	3 (27.3)	0	0	0

Data are mean ± SD or number (%). EGFR: Epithelial growth factor receptor; ECOG PS: Eastern Cooperative Oncology Group performance status.